RaQualia Pharma is focused on innovative drug discovery, particularly in the development of novel pharmaceuticals aimed at treating intractable diseases. One of their key technologies is the Potassium-Competitive Acid Blocker (P-CAB), specifically the compound tegoprazan, which offers a new approach to inhibiting gastric acid secretion. This technology is designed to provide faster and more sustained relief for conditions like gastroesophageal reflux disease compared to traditional proton pump inhibitors. Additionally, RaQualia is advancing several other therapeutic candidates, including a P2X7 receptor antagonist for chronic pain, a ghrelin receptor agonist for conditions such as cancer-related anorexia, and a sodium channel blocker aimed at pain management.

The company also emphasizes its commitment to veterinary medicine, with a focus on developing treatments for gut motility disorders in animals through a highly selective 5-HT4 agonist. RaQualia's pipeline includes a range of compounds at various stages of development, showcasing their dedication to addressing unmet medical needs across both human and veterinary health. Their research efforts are characterized by collaborations with other pharmaceutical companies, which enhance their capabilities in bringing innovative therapies to market.

Japan

RaQualia Pharma - We are an innovative pharmaceutical company
leveraging our expertise in drug discovery research and our collaborations
with state-of-the-art academic research institutions.

RaQualia Pharma

Company Details